480 related articles for article (PubMed ID: 25200104)
81. The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.
Krasowski MD; Ai N; Hagey LR; Kollitz EM; Kullman SW; Reschly EJ; Ekins S
BMC Biochem; 2011 Feb; 12():5. PubMed ID: 21291553
[TBL] [Abstract][Full Text] [Related]
82. Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function.
Milona A; Owen BM; Cobbold JF; Willemsen EC; Cox IJ; Boudjelal M; Cairns W; Schoonjans K; Taylor-Robinson SD; Klomp LW; Parker MG; White R; van Mil SW; Williamson C
Hepatology; 2010 Oct; 52(4):1341-9. PubMed ID: 20842631
[TBL] [Abstract][Full Text] [Related]
83. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
[TBL] [Abstract][Full Text] [Related]
84. Bile acids increase steroidogenesis in cholemic mice and induce cortisol secretion in adrenocortical H295R cells via S1PR2, ERK and SF-1.
Liu L; Panzitt K; Racedo S; Wagner M; Platzer W; Zaufel A; Theiler-Schwetz V; Obermayer-Pietsch B; Müller H; Höfler G; Heinemann A; Zollner G; Fickert P
Liver Int; 2019 Nov; 39(11):2112-2123. PubMed ID: 30664326
[TBL] [Abstract][Full Text] [Related]
85. Bile acid receptors and the kidney.
Herman-Edelstein M; Weinstein T; Levi M
Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
[TBL] [Abstract][Full Text] [Related]
86. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
[TBL] [Abstract][Full Text] [Related]
87. Nuclear receptors in acute and chronic cholestasis.
Gonzalez-Sanchez E; Firrincieli D; Housset C; Chignard N
Dig Dis; 2015; 33(3):357-66. PubMed ID: 26045270
[TBL] [Abstract][Full Text] [Related]
88. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
Verbeke L; Farre R; Verbinnen B; Covens K; Vanuytsel T; Verhaegen J; Komuta M; Roskams T; Chatterjee S; Annaert P; Vander Elst I; Windmolders P; Trebicka J; Nevens F; Laleman W
Am J Pathol; 2015 Feb; 185(2):409-19. PubMed ID: 25592258
[TBL] [Abstract][Full Text] [Related]
89. ENDOCRINOLOGY IN PREGNANCY: Metabolic impact of bile acids in gestation.
Fan HM; Mitchell AL; Williamson C
Eur J Endocrinol; 2021 Mar; 184(3):R69-R83. PubMed ID: 33434155
[TBL] [Abstract][Full Text] [Related]
90. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
[TBL] [Abstract][Full Text] [Related]
91. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.
Petrescu AD; DeMorrow S
Cells; 2021 Jul; 10(8):. PubMed ID: 34440614
[TBL] [Abstract][Full Text] [Related]
92. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A
Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532
[TBL] [Abstract][Full Text] [Related]
93. FXR: a target for cholestatic syndromes?
Cai SY; Boyer JL
Expert Opin Ther Targets; 2006 Jun; 10(3):409-21. PubMed ID: 16706681
[TBL] [Abstract][Full Text] [Related]
94. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
95. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
[TBL] [Abstract][Full Text] [Related]
96. Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors.
Shin DJ; Wang L
Handb Exp Pharmacol; 2019; 256():51-72. PubMed ID: 31230143
[TBL] [Abstract][Full Text] [Related]
97. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552
[TBL] [Abstract][Full Text] [Related]
98. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Silveira MG; Lindor KD
Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
[TBL] [Abstract][Full Text] [Related]
99. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.
Miyazaki-Anzai S; Masuda M; Kohno S; Levi M; Shiozaki Y; Keenan AL; Miyazaki M
J Lipid Res; 2018 Sep; 59(9):1709-1713. PubMed ID: 29976576
[TBL] [Abstract][Full Text] [Related]
100. Beneficial effect of resveratrol on α‑naphthyl isothiocyanate‑induced cholestasis via regulation of the FXR pathway.
Ding L; Zhang B; Li J; Yang L; Wang Z
Mol Med Rep; 2018 Jan; 17(1):1863-1872. PubMed ID: 29138819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
